GSK Reports H1 2025 Revenue Exceeding $20 Billion and Terminates Two Phase III Programs

On July 30, GlaxoSmithKline (GSK) released its H1 2025 financial report, covering the first half of the year.Revenue of 15.502 billion pounds (20.157 billion US dollars), a year-on-year increase of 5%(Calculated at fixed exchange rates, same below)。R&D investment of 3.486 billion pounds($4.532 billion), an increase of 22% year-on-year.

GSK's business is mainly divided intoSpecialty Medicines, Vaccines, and General MedicinesThree segments respectively contributed £62.60 billion in the first half of the year.($8.141 billion, +16%)、4.186 billion pounds($5.443 billion, +1%)、5.056 billion pounds($6.573 billion, -3%)Performance income.

GSK's oncology sector growth is mainly attributed toAnemia Patients with Myelofibrosis Drug Ojjaara/Omjjara(Moloxini, launched in September 2023)The launch of, andPD-1 Monoclonal Antibody Jemperli(Dostarlimab, launched in April 2021)Driven by the expansion of new indications and increased market penetration, the sales of the two products in the first half of the year reached 2.50 billion pounds (+87%) and 3.70 billion pounds (+>100%), respectively.

In the respiratory/immunology field, Nucala (mepolizumab) and Benlysta (belimumab) contributed sales of 942 million pounds (+13%) and 810 million pounds (+23%) respectively to GSK.

In the HIV field, GSK holds long-acting products with continuously growing sales. Cabenuva (Cabotegravir + Rilpivirine), Apretude (Cabotegravir), and Dolutegravir generated revenues of £635 million (+42%), £190 million (+56%), and £2.674 billion (+2%), respectively.

In terms of vaccines, GSK product sales remained weak, with only meningitis vaccines performing relatively well. Meningitis(Including Bexsero and Menveo)Achieved double-digit growth, injecting new momentum into GSK's vaccine sector, with sales reaching £729 million in the first half of the year, a year-on-year increase of 21%. 

In the second quarter, GSK terminatedTIGIT Monoclonal Antibody BelrestotugFor non-small cell lung cancer and ibrexafungerp forInvasive Candidiasis IIIPhase Clinical. On May 13 this year, due toGALAXIES Lung-201 StudyFailed to reach the primary endpoint,GSK Decides to Terminate the Belrestotug Development Project and End Cooperation withiTeos'sCooperation.

Source: GSK Official Website

In 2025, to offset the impact of a sluggish pharmaceuticals business, GSK continues to strengthen its efforts in mergers and acquisitions. Data from the Insight database shows that GSK this yearA total of 5 pharmaceutical deals were reached., including acquisitionsIDRX, co-developed AID351 with Chugai Pharmaceutical Co., Ltd., and introduced from HengruiPDE3/4 InhibitorHRS-9821, etc.

In the second half of 2025, GSK will reach the following milestonesEventItems, including IL5 monoclonal antibodyDemochizumab (Depemokimab will secure its first approval in the United States.

Source: GSK Official Website

GSK ExpectationsRevenue growth of 3~5% in 2025.

2025 H1 MNC Earnings Season Underway,Insight database has compiled the disclosed semi-annual reports.，Scan the QR code below and reply with the keywordMNC Semi-Annual ReportAvailable for free(Continuously updating...)。

Cover Source:Corporate Logo

Disclaimer:This article is for information sharing only, and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment options. If necessary, please consult and contact正规医疗机构.

Editor: Crescent

PR Coordination: WeChat insightxb